Quantum Leap Healthcare Collaborative

Media Center

Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.
Close
Close
I-SPY Email List Sign-up

Latest Press Release

SABCS 2017: Long-term efficacy results from the I-SPY 2 TRIAL indicate pathological complete response (pCR) is a powerful predictor for breast cancer survival

Data Presented at San Antonio Breast Cancer Symposium Show Significant and Clinically Impactful Relationship Between pCR and Event-Free Survival in High-Risk Breast Cancer.

December 7, 2017

Backgrounders

June 1, 2018
Executive Summary: the I-SPY 2 TRIAL
Some history of the I-SPY TRIAL
May 31, 2018
I-SPY 2 Patient Brochure
Introductory information on the I-SPY 2 TRIAL.
May 29, 2018
Patient Story: Why I chose I-SPY 2
A patient's perspective on participating in the I-SPY 2 TRIAL.
May 29, 2018
Patient Story: My experience as an I-SPY 2 patient
A patient's perspective on participating in the I-SPY 2 TRIAL.